AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
Analyst coverage unavailable
Fundamentals
Fundamentals institutional score is 0 using growth durability 0.0.
Valuation
Valuation institutional score is 80 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
No usable analyst target or recommendation data was available.
Technical Structure
Technicals institutional score is 96 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 7 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. valuation and technical structure provide support, while fundamentals and market sentiment remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
—
Current
597.17
Overvalued
686.75
Undervalued
507.60
5Y Average
29.34
Current
12.69
Overvalued
52.46
Undervalued
13.41
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
COHANCE LIFESCIENCES LTD COHANCEPharmaceuticals | -23.1% | 5.0% | 162.0x Premium | +203% vs avg | -52.7% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 28.0x Undervalued | -48% vs avg | +43.4% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 43.8x Undervalued | -18% vs avg | +45.4% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.7x Undervalued | -18% vs avg | -25.8% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Undervalued | -28% vs avg | +31.7% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 37.5x Undervalued | -30% vs avg | +29.9% |
GLAND PHARMA LIMITED GLANDPharmaceuticals | +22.3% | 16.0% | 42.9x Undervalued | -20% vs avg | +34.3% |
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 31.2x Undervalued | -42% vs avg | +22.1% |
SUVEN LIFE SCIENCES LTD is compared against the Pharmaceuticals cohort. Peers include COHANCE LIFESCIENCES LTD, ALIVUS LIFE SCIENCES LTD, AKUMS DRUGS AND PHARMA L — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹1.52 CrApr 2026Free cash flow
₹-26 CrFY25Interest
₹-0.16 CrProfit conversionPerformance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Apr 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2016 | Apr 2026 |
|---|---|---|
| Sales | 169 | 1.52 |
| Interest | 1.68 | 0.16 |
| Depreciation | 5.57 | 1.58 |
All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.